Mark Kowalski
2020 - ProNAi Therapeutics
In 2020, Mark Kowalski earned a total compensation of $2M as Chief Medical Officer at ProNAi Therapeutics, a 125% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $178,231 |
|---|---|
| Option Awards | $1,393,652 |
| Salary | $445,578 |
| Other | $5,218 |
| Total | $2,022,679 |
Kowalski received $1.4M in option awards, accounting for 69% of the total pay in 2020.
Kowalski also received $178.2K in non-equity incentive plan, $445.6K in salary and $5.2K in other compensation.
Rankings
In 2020, Mark Kowalski's compensation ranked 5,450th out of 13,090 executives tracked by ExecPay. In other words, Kowalski earned more than 58.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,450 out of 13,090 | 58th |
Division Manufacturing | 2,242 out of 5,618 | 60th |
Major group Chemicals And Allied Products | 892 out of 2,251 | 60th |
Industry group Drugs | 769 out of 1,951 | 61st |
Industry Pharmaceutical Preparations | 574 out of 1,456 | 61st |
Source: SEC filing on April 23, 2021.
Kowalski's colleagues
We found three more compensation records of executives who worked with Mark Kowalski at ProNAi Therapeutics in 2020.